As a young, dynamic and creative molecular diagnostics company, we have specialized in simple and rapid solutions for the diagnosis of severe infectious diseases in hospitalized patients. We help to combat infections effectively and detect antibiotic resistance at an early stage.
Curetis Publishes Business and Financial Update for the First Nine Months of 2017
Curetis initiates U.S. FDA study for Unyvero Invasive Joint Infections Cartridge
37ème Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse - Paris, France - December 18 to 19, 2017
19 Journées Nationales d’Infectiologie, Nantes, France - June 13 to 15, 2018